SCHEMBL6800837

SCHEMBL6800837

COc1ccc(-n2c(=O)n(O)c(=O)c3cc(F)c(N4CCN(C)CC4)cc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.48
KMT2A Q03164 4/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 3/20 0.42
GAA P10253 1/20 0.42
POLB P06746 1/20 0.41
HTR7 P34969 4/20 0.41
THRB P10828 1/20 0.41
DRD3 P35462 1/20 0.40
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801982 0.92 THRB (0.42) TRPV4KMT2ALMNAALDH1A1GAA
SCHEMBL6798420 0.90 HTR7 (0.44) TRPV4KMT2ALMNAMEN1ALDH1A1
SCHEMBL6807011 0.89 LMNA (0.55) TRPV4KMT2ALMNAMEN1ALDH1A1
SCHEMBL6800528 0.84 KMT2A (0.45) KMT2ALMNAMEN1ALDH1A1GAA
SCHEMBL6798617 0.84 PRKD3 (0.44) TRPV4KMT2AALDH1A1GAATHRB
Hydrochloric Acid SCHEMBL7007125 0.83 PRKD3 (0.43) TRPV4KMT2AALDH1A1GAAERCC5
SCHEMBL6801538 0.82 KMT2A (0.46) KMT2ALMNAMEN1ALDH1A1GAA
SCHEMBL6801016 0.82 KMT2A (0.44) KMT2ALMNAMEN1ALDH1A1GAA
SCHEMBL6806693 0.82 BRPF1 (0.43) LMNAALDH1A1GAAHTR7THRB
SCHEMBL6802535 0.81 TRPV4 (0.42) TRPV4KMT2ALMNAMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A TRPV4 2869/4885KMT2A 3798/4885LMNA 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.